Varney M D, Appelt K, Kalish V, Reddy M R, Tatlock J, Palmer C L, Romines W H, Wu B W, Musick L
Agouron Pharmaceuticals, Inc., San Diego, California 92121.
J Med Chem. 1994 Jul 22;37(15):2274-84. doi: 10.1021/jm00041a005.
The X-ray crystal-structure-based design, synthesis, computational evaluation, and activity of a novel class of HIV protease inhibitors are described. The initial lead compounds 2 and 3 were designed by modeling replacement groups for the C-terminal Val-Val-OCH3 of a known hydroxyethylene inhibitor into the active site of the reported crystal structure of HIV protease complexed with MVT-101. The lead compound 2 was found to be a modest inhibitor with a Ki = 1.67 microM. The X-ray crystal structure of compound 2 complexed with HIV protease was solved and used for subsequent design. The lead compound 3 was found to be a more potent inhibitor with Ki = 0.2 microM, and the structure of it complexed with HIV protease was also solved and used for subsequent design. Modification of both the C-terminus and N-terminus of indole 3 resulted in compounds with Ki = 30 nM. Using the crystal structure of compounds 2 and 3 with HIV protease as a starting point, the thermodynamic cycle perturbation molecular dynamics method was applied to a select group of compounds in order to test the accuracy of this type of computation within a series of closely related compounds.
本文描述了一类新型HIV蛋白酶抑制剂基于X射线晶体结构的设计、合成、计算评估及活性。最初的先导化合物2和3是通过将已知羟基乙烯抑制剂C端的缬氨酸-缬氨酸-甲氧基的取代基团模拟到与MVT-101复合的HIV蛋白酶报道晶体结构的活性位点中设计出来的。发现先导化合物2是一种中等强度的抑制剂,其Ki = 1.67微摩尔。解析了化合物2与HIV蛋白酶复合的X射线晶体结构,并用于后续设计。发现先导化合物3是一种更有效的抑制剂,其Ki = 0.2微摩尔,并且也解析了它与HIV蛋白酶复合的结构并用于后续设计。对吲哚3的C端和N端进行修饰得到了Ki = 30纳摩尔的化合物。以化合物2和3与HIV蛋白酶的晶体结构为起点,将热力学循环微扰分子动力学方法应用于一组选定的化合物,以测试在一系列密切相关的化合物中这种计算类型的准确性。